All In Biotech

Drug Trial Radar · NCT02193334

Phase I/II Study of KP-100IT in Acute Spinal Cord Injury

A Phase I/II Study to Evaluate the Safety and Efficacy of Intrathecal Injection of KP-100IT in Subjects With Acute Spinal Cord Injury

Last checked: Nov 19, 2026Latest source record: Jun 5, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

45

Actual

Start

Jun 30, 2014

Primary completion

Dec 21, 2017

Study completion Jul 31, 2018

Sponsor

Lead sponsor
Kringle Pharma, Inc.Industry
Sponsor type
Industry
First posted
Jul 17, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is randomized, double-blind, placebo-controlled Phase I/II study designed to evaluate safety and efficacy of KP-100IT, code of Hepatocyte Growth Factor (HGF) formulation for intrathecal injection, as a treatment for acute spinal cord injury. The study is conducted at two clinical sites in Japan.

Conditions

  • Spinal Cord Injuries

Interventions

  • KP-100ITDrug

  • PlaceboDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number and degree of adverse eventsTime frame: 24 weeks
  2. Change of ASIA (American Spinal Injury Association) motor score from baseline at 24 weeksTime frame: 24 weeks

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Spinal Injuries Center

    Iizuka, Fukuoka, Japan

  • Hokkaido Chuo Rosai Hospital Sekison Center

    Bibai, Hokkaido, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.